04-30 VIVUS BV Announces Qsiva Price Reduction Across Nordics And Poland CI
03-18 Vivus BV Confirms QSIVA Price Reduction Is Now Effective Across Nordics And Poland CI
03-10 Vivus Bv, A Subsidiary of Vivus Llc Announces Qsiva Price Reduction Across Nordics and Poland CI
01-26 VIVUS LLC Announces the Results of a Randomized Trial Evaluating the Effect of QSYMIA CI
01-07 VIVUS Introduces Lower Pricing on QSYMIA at Costco Locations Across Hawaii CI
04/09/25 VIVUS Showcases Leadership in Obesity Management at the 2025 International Congress on Obesity and MEtabolic Syndrome CI
27/05/25 VIVUS Announces Qsymia Now Available at Costco Pharmacies Nationwide CI
14/04/25 VIVUS Announces Enrollment of First Patient in Phase 2 Clinical Trial Assessing Ethanol-Free Carmustine as a Component of High-Dose Chemotherapy Prior to Transplant in Patients with Hodgkin or Non-Hodgkin Lymphoma CI
10/03/25 VIVUS Launches QSYMIA in the United Arab Emirates CI
23/10/24 VIVUS Announces Label Update for QSYMIA CI
30/05/24 Vivus, Inc. Announces the Publication of New Clinical Trial Data Demonstrating That Pancreaze Helped to Stabilize Weight in Patients Undergoing Chemotherapy for the Treatment of Pancreatic Ductal Adenocarcinoma CI
22/04/24 VIVUS LLC Announces It Will Provide Telehealth to Patients Through an Enhanced 'Engage' Program in Collaboration with UpScriptHealth CI
28/11/23 VIVUS LLC Announces Positive Topline Data from a Post-Marketing Study to Evaluate the Effect of QSYMIA CI
10/01/23 VIVUS, Inc. Promotes Santosh T. Varghese to President VIVUS Global Pharmaceutical Development CI
20/07/22 FDA Approves VIVUS LLC's QSYMIA® for the Treatment of Obesity in Adolescents Ages 12-17 CI
14/12/20 VIVUS : Receives Court Approval of Joint Chapter 11 Plan of Reorganization AQ
11/12/20 VIVUS, Inc. Emerged from Bankruptcy CI
10/12/20 Revised Second Amended Reorganization Plan & Disclosure Statement Approved for VIVUS, Inc. CI
17/11/20 First Motion for Exclusivity Period Extension Approved For VIVUS, Inc. CI
16/11/20 VIVUS : Seeks Bankruptcy Court Approval of Second Amended Joint Chapter 11 Plan of Reorganization and Existing Stock Record Date AQ
16/11/20 VIVUS INC : Other Events, Financial Statements and Exhibits (form 8-K) AQ
10/11/20 Second Amended Joint Pre-Packaged Reorganization Plan Filed by VIVUS, Inc. CI
04/11/20 First Motion for Exclusivity Period Extension Filed by VIVUS, Inc. CI
20/10/20 Motion for Asset Sale Filed by VIVUS, Inc. CI
18/08/20 First Amended Joint Pre-Packaged Reorganization Plan Filed by VIVUS, Inc. CI
No results match your criteria
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!